Home › Funds › Opaleye Management Inc. › BBOT
Opaleye Management Inc. position in BBOT
BridgeBio Oncology Therapeutic Inc · Health Care
Opaleye Management Inc. reported holding 700,000 shares of BBOT (BridgeBio Oncology Therapeutic Inc) in its Q2 2026 13F filing — a position valued at US$5.3M, representing 0.48% of its reported portfolio and ranking #34 among its reported holdings. Opaleye Management Inc. has disclosed BBOT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Opaleye Management Inc.'s BBOT position evolved
Opaleye Management Inc. first disclosed a stake in BBOT in Q1 2026 at 53,282 shares (US$477K). The position peaked in Q2 2026 at 700,000 shares, worth US$5.3M. Across 2 filings, Opaleye Management Inc. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 700,000 shares valued at US$5.3M — an increase of 646,718 shares quarter over quarter.. Notable position changes include a 1214% increase in Q2 2026 (shares fell 46% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 53.28K | $476.87K | New |
| Q2 2026 | 700.00K | $5.33M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BBOT and 13F data
BBOT (BridgeBio Oncology Therapeutic Inc) is a Health Care company. 74 other funds we track also report a position in BBOT — the largest reported positions include Cormorant Asset Management, LP (US$136.2M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$37.2M), Omega Fund Management, LLC (US$25.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBOT
- Cormorant Asset Management, LP 17.88M sh · $136.23M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.89M sh · $37.23M · Q2 2026
- Omega Fund Management, LLC 3.29M sh · $25.07M · Q2 2026
- Alphabet Inc. 2.82M sh · $21.51M · Q2 2026
- EcoR1 Capital, LLC 2.82M sh · $21.51M · Q2 2026
- Enavate Sciences GP, LLC 2.63M sh · $20.02M · Q2 2026
- Novo Holdings A/S 2.25M sh · $17.14M · Q2 2026
- Laurion Capital Management LP 2.00M sh · $15.26M · Q2 2026
- Aisling Capital Management LP 1.02M sh · $7.76M · Q2 2026
- Catalio Capital Management, LP 318.41K sh · $2.43M · Q2 2026
- Casdin Capital 282.31K sh · $2.15M · Q2 2026
- Avidity Partners Management LP 43.85K sh · $334.16K · Q2 2026
More on Opaleye Management Inc.
FAQ
How long has Opaleye Management Inc. held BBOT?
Opaleye Management Inc. has disclosed BBOT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Opaleye Management Inc.'s current position in BBOT?
As of Q2 2026, Opaleye Management Inc. holds 700.00K shares of BBOT (BridgeBio Oncology Therapeutic Inc), valued at $5.33M, representing 0.48% of its reported portfolio and ranking #34.
Has Opaleye Management Inc. been buying or selling BBOT?
In the latest 13F filing (Q2 2026), Opaleye Management Inc. increased its position in BBOT. The position peaked in Q2 2026 at 700.00K shares.
Which other funds hold BBOT?
Other major institutional holders of BBOT include Cormorant Asset Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Omega Fund Management, LLC, among 74 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.